METHODS AND SYSTEMS FOR IMPROVED BIOAVAILABILITY OF ACTIVE PHARMACEUTICAL INGREDIENTS INCLUDING ESOMEPRAZOLE

摘要

The present disclosure relates to delivery systems and methods for increasing the bioavailability and increasing the absorption rate by monolithic enteric capsule administration to humans of active ingredients compared to the bioavailability of active ingredients enterically coated for modified release or gastric protection, particularly acid sensitive active ingredients such as esomeprazole, omeprazole, and other proton pump inhibitors, systems for delivering active pharmaceutical ingredients to humans or animals via monolithic enteric capsules, and improved methods of treating gastrointestinal disorders with such methods and delivery systems.